A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
Market
0.0%
Details
- Resolved Date
- 2/12/26
- Study Completion
- 4/30/26
- Company
- H. Lundbeck A/S
- Ticker
- LUN.CO
- Type
- Trial Status
- Active Not Recruiting
- Trial Size
- 874
- Volume
- $0
- NCT
- NCT06323928
- Drug Description
- The purpose of this trial is to determine which doses of Lu AG09222 are recommended to help prevent migraines. People who join this trial have already tried 1 to 4 other available medications to prevent their migraines, but these medications have not helped them.
Resolution Evidence
- Outcome
- YES
- Status
- Resolved
- Settlement Date
- 4/1/26 UTC
- Executive Summary
Lundbeck publicly reported positive Phase IIb top-line results for PROCEED (NCT06323928), stating the IV part met the primary endpoint with a statistically significant reduction vs placebo in monthly migraine days. ClinicalTrials.gov confirms this is the exact Phase 2 trial in question.
Sources
Sponsormb.cision.com2/12/26
Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention
Sponsor says the IV part of PROCEED (NCT06323928) met its primary endpoint, showing a statistically significant difference vs placebo in change from baseline in monthly migraine days over weeks 1-12.
View source
ClinicalTrialsclinicaltrials.gov2/2/26
Study Details | NCT06323928 | A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments
ClinicalTrials.gov identifies NCT06323928 as the Phase 2 PROCEED trial of Lu AG09222 vs placebo in migraine patients with unsuccessful prior preventive treatments.
View source
Activity Feed
No activity entries match the current filters for this market.
Model Positions
